Tranexamic acid in trauma: how should we use it?
Roberts, I; (2015) Tranexamic acid in trauma: how should we use it? Journal of thrombosis and haemostasis, 13 Suppl 1. S195-9. ISSN 1538-7933 DOI: https://doi.org/10.1111/jth.12878
Abstract
Tranexamic acid (TXA) reduces blood loss by inhibiting the enzymatic breakdown of fibrin. It is often used in surgery to decrease bleeding and the need for blood transfusion. In 2011, results from a multi-center, randomized, and placebo-controlled trial (CRASH-2 trial) showed that TXA (1 g loading dose over 10 min followed by an infusion of 1 g over 8 h) safely reduces mortality in bleeding trauma patients. Initiation of TXA treatment within 3 h of injury reduces the risk of hemorrhage death by about one-third, regardless of baseline risk. Because it does not have any serious adverse effects, TXA can be administered to a wide spectrum of bleeding trauma patients. Limiting its use to the most severely injured or those with a diagnosis of 'hyperfibrinolysis' would result in thousands of avoidable deaths. A clinical trial (CRASH-3 trial) of TXA in patients with traumatic brain injury is now in progress.
| Item Type: | Article |
|---|---|
| Faculty and Department: | Faculty of Epidemiology and Population Health > Dept of Population Health (2012- ) > Dept of Nutrition and Public Health Interventions Research (2003-2012) Faculty of Epidemiology and Population Health > Dept of Population Health (2012- ) |
| PubMed ID: | 26149023 |
| Web of Science ID: | 356677500026 |
| URI: | http://researchonline.lshtm.ac.uk/id/eprint/2235979 |
Statistics
Accesses by country - last 12 months | Accesses by referrer - last 12 months |
Actions (login required)
 |
Edit Item |
